Luminary Therapeutics, Inc.
Publicly observedMinneapolis, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Minneapolis | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Luminary Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | MNKBAEZHWJS1 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Jul 2023Publicly observed
NIH SBIR/STTR award: Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies
USD 586,799.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jul 2023Publicly observed
NIH SBIR/STTR award: Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies
USD 1,463,315.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.